bpc 157 compounding restrictions fda Exciting news for peptides coming out of today's committee hearing! The Pharmacy Advisory Committee voted 8-6 to recommend adding BPC- to the 503A Bulks List for use in compounding for FDA's own advisory committee voted

FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA Panel Narrowly Backs Lifting Restrictions on Peptides Backed by RFK Jr. MedPage Today FDA's Overreach on Compounded Peptides A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring!

SKU: 60026089034 · From webdevsolutions.tech